PERSISTENT

INFECTION

CLINICAL VALIDATION

Clinically Validated Pathology-based AI Prediction of Persistent Infection of Active SARS-CoV-2

​

SWITZERLAND, THURSDAY, 30 APRIL 2020 2:30 PM CET

The prevalence of asymptomatic chronic infection of SARS-CoV-2 in discharged patients is one of our contrarian pathology-based clinical predictions, because all known coronaviridae don’t exhibit viral latency and antibodies in the convalescent plasma would eradicate residual SARS-CoV-2...On 28 April 2020, the first evidence of active virus particles detected in a ready-to-discharge patient who had three consecutive negative PCR tests yet died of cardiac arrest, was reported in a letter to the editor in Cell Research...

REMDESIVIR

POST-TREATMENT

REBOUND

​

CLINICAL VALIDATION

Clinically Validated Pathology-based AI Prediction of Remdesivir-specific Post-treatment Rebound of SARS-CoV-2

​

SWITZERLAND, THURSDAY, 30 APRIL 2020 13:10 PM CET

Although remdesivir was almost universally believed as the most promising curative treatment candidate for COVID-19 based on strong compassionate use data2 and in vitro data3 published in January 2020, we announced a contrarian pathology-based clinical prediction on 23 February 2020 that remdesivir would be an effective but non-curative treatment for severely ill COVID-19 patients and remdesivir would present the clinical risk of post-treatment viral rebound...

PHASE II

CLINICAL TRIAL

CLINICAL VALIDATION

Phase 2 Clinical Trial of Demiurge AI-Discovered Etoposide Treatment for COVID-19 Severely Ill Patients

​

SWITZERLAND, SATURDAY, 25 APRIL 2020 8:30 PM CET

On 28 February 2020, we shared the pathology-based prospective prediction that the combination of irinotecan and etoposide could potentially be an exceptionally effective treatment to protect critically ill patients from death caused by COVID-19-specific cytokine storms triggered by sepsis, ARDS, and other fatal comorbidities... On 22 April 2020, a phase 2 clinical trial (NCT043566902) has been initiated by Boston Medical Center to investigate the safety and efficacy of etoposide in severely ill COVID-19 patients with clinical onset of cytokine storm...

ACE2 EXPRESSION

AS A PREDICTIVE BIOMARKER

CLINICAL VALIDATION

Clinically Validated Pathology-based AI Prediction of ACE2 Expression as A Predictive Biomarker of COVID-19 Mortality

​

SWITZERLAND, THURSDAY, 2 APRIL 2020 4:30 PM CET

The SARS-CoV-2-mediated post-entry suppression of ACE2 mRNA expression in host cells is one of our contrarian pathology-based clinical predictions, because it appears to be self-conflicting for SARS-CoV-2 to bind ACE2 via S to enable viral entry on the one hand, and to suppress ACE2 expression to enhance viral replication on the other hand...We also shared the further pathology-based clinical prediction that ACE2 deficiency is a core causal co-driver of COVID-19 clinical outcomes...

PERSISTENT

INFECTION

CLINICAL VALIDATION

Clinically Validated Pathology-based AI Prediction of Persistent Infection of SARS-CoV-2

​

SWITZERLAND, WEDNESDAY, 1 APRIL 2020 6:00 PM CET

On March 30 2020, the first study on RP patients, “Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test”3, was uploaded to medRxiv. Its data on 262 discharged patients in China have robustly validated our contrarian prediction of the prevalence of asymptomatic chronic infection of SARS-CoV-2 in discharged patients...

AI-DISCOVERED

COMPLETE AETIOLOGY &

TREATMENT

RATIONALE

COVID-19 DISEASE MODEL

& PREDICTION

Demiurge Technologies Announces the Pre-publication of the Detailed Aetiology and Treatment Rationale for Critically Ill COVID-19 Patients

​

SWITZERLAND, TUESDAY, 24 MARCH 2020 1:30 PM CET

Demiurge is responding to the 2019 novel coronavirus (COVID-19) pandemic through the appropriate use of the Demiurge Unified AI Platform for disease modeling, clinical prediction, and drug discovery that can make rapid and accurate drug discoveries for diseases with limited available clinical data. Demiurge is the world's first company that has discovered the detailed aetiology of COVID-19 that consistently explains the clinical features of COVID-19 and the mechanism-of-action-based scientific rationale of the candidate treatments for COVID-19 patients, all of which have been achieved in 6 weeks from 7. February 2020 to 20. March 2020...

AI-DISCOVERED

COMPLETE AETIOLOGY &

TREATMENT

RATIONALE

COVID-19 DISEASE MODEL

& PREDICTION

Demiurge AI Discovers the Complete Aetiology of COVID-19 and the Optimal Treatment Strategy for COVID-19

​

SWITZERLAND, SATURDAY, 7 MARCH 2020 5:15 PM CET

Based on the deep analyses of published studies, clinical data and case reports on COVID-19 and our previously announced four AI-based discoveries for COVID-19, we hereby officially announce the 5th AI-based discovery of the complete aetiology of COVID-19 as below: Viral survival strategy...Viral infection stages...Viral entry...Viral replication and egress...Viral microenvironment...Viral adaptive mutation...Viral latent Infection...Viral latent adversity...COVID-19 is an unprecedented coronavirus that causes both acute respiratory illnesses for symptomatic patients and chronic systemic disorders for asymptomatic carriers....

WHO ESSENTIAL MEDICINE

TREATMENTS PROPOSAL

DRUG DISCOVERY

& PREDICTION

Demiurge AI Discovers WHO essential medicine combination treatments for reducing the mortality rate of critically ill COVID-19 patients

​

SWITZERLAND, FRIDAY, 28 FEBRUARY 2020 10:50 PM CET

It is paramount to develop effective treatments for critically ill patients because COVID-19 has higher mortality rate of critically ill patients than SARS-CoV and MERS-CoV. It is equally important to develop scalable treatments that are cost-effective and globally available so as to reduce the mortality rate of COVID-19 in various countries of different infection control capabilities. We hereby officially announce the discovery of the following scalable effective candidate treatments for reducing the mortality rate of critically ill COVID-19 patients worldwide...

REMDESIVIR

CHILOROQUINE

PI3K INHIBITORS

DRUG DISCOVERY

& PREDICTION

Demiurge AI Discovers the Clinical Benefits and Risks of Remdesivir, Chloroquine, and PI3K inhibitors against 2019 Novel Coronavirus (COVID-19)

​

SWITZERLAND, SUNDAY, 23 FEBRUARY 2020 7:35 AM CET

Demiurge is responding to the outbreak of the 2019 novel coronavirus (COVID-19) through the appropriate use of our AI platform of discovering novel therapeutic solutions and predicting clinical trial outcomes. We are conducting deep analyses of published studies and clinical data on COVID-19 against our precise broad-spectrum virology models. In addition to the previous discoveries of multiple PI3K inhibitors as novel therapeutic options for COVID-19, we hereby officially announce further discoveries of the clinical benefits and risks of Remdesivir, Chloroquine, and PI3K inhibitors against COVID-19...

AI-DISCOVERED

PI3K-P110𝛂

INHIBITORS

TREATMENTS

DRUG DISCOVERY

& PREDICTION

Demiurge AI Discovers PI3K-p110α Inhibitors as a Novel Candidate Monotherapy and PI3K-p110δ Inhibitors + PD-1 Inhibitors as a Novel Candidate Combination Therapy Selective for 2019 Novel Coronavirus (COVID-19)

​

SWITZERLAND, SUNDAY, 16 FEBRUARY 2020 8:55 AM CET

In addition to the initial discovery of PI3K inhibitors as a novel candidate treatment for COVID-19 in our press release dated 14. February 2020, we hereby officially announce further discoveries along the lines of PI3K inhibitors: PI3K-p110α selective inhibitors would have a better efficacy and safety profile than PI3K-p110δ selective inhibitors for COVID-19...

AI-DISCOVERED

PI3K 

INHIBITORS

TREATMENTS

DRUG DISCOVERY

& PREDICTION

Demiurge AI Discovers PI3K inhibitors as a Novel Candidate Treatment Selective for 2019 Novel Coronavirus (COVID-19)

​

SWITZERLAND, FRIDAY, FEBRUARY 14, 2020 11:30 AM CET

Demiurge is responding to the outbreak of 2019 novel coronavirus (COVID-19) through the appropriate use of our AI platform of discovering novel therapeutic solutions and predicting clinical trial outcomes. After deep analysis of published studies and data on COVID-19 against our precise broad-spectrum virology models, we hereby officially announce the discovery of phosphoinositide 3-kinase inhibitors (PI3K inhibitors) that can be potentially repurposed into an optimally effective and safe therapeutic solution selectively against COVID-19, though PI3K inhibitors may not be equally effective or safe against SARS coronavirus or MERS coronavirus...